Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 2/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.62 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.57 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747230 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL2033285 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL23149534 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL20850065 | 1.00 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21715304 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL26067682 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21715305 | 0.99 | TGM2 (0.69) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL21184323 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL19325472 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL | |
| SCHEMBL18763616 | 0.95 | TGM2 (0.68) | TGM2FUT5KRASNT5ERNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531842-A2 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | ATEA Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12263229-B2 | Induction of osteogenesis by delivering BMP encoding RNA | ETHRIS GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-20250082656-A1 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024094027-A1 | BLOCKING SEQUENCE, KIT THEREOF, AND METHOD FOR USING SAME | 深圳鸿生生物科技有限公司 | 2024-05-10 | — | — | WO | disclosed |
| EP-3836903-B1 | LIPID-BASED FORMULATIONS CONTAINING SALTS FOR THE DELIVERY OF RNA | ETHRIS GMBH (DE) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023230348-A2 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| EP-3784284-B1 | LIPID-BASED FORMULATIONS FOR THE DELIVERY OF RNA | ETHRIS GMBH (DE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115997033-A | Catalytic control sequencing by synthetic generation of traceless DNA | 伊鲁米纳公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4151739-A1 | IMPROVED TRANSPOSON SYSTEM FOR GENE DELIVERY | T-CURX GmbH (DE) | 2023-03-22 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | TGM2 2235/4885FUT5 300/4885KRAS 2645/4885 |
| US-12263229-B2 | Induction of osteogenesis by delivering BMP encoding RNA | BMP2, BMP1, BMP6 | TGM2 4109/4885FUT5 4455/4885KRAS 3796/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | TGM2 1465/4885FUT5 77/4885KRAS 2417/4885 |
| US-20250082656-A1 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | FCGR3B, HAVCR2, FCGR2A | TGM2 4064/4885FUT5 82/4885KRAS 3897/4885 |
| US-12023371-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | TGM2 3781/4885FUT5 641/4885KRAS 2697/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | TGM2 1500/4885FUT5 175/4885KRAS 3197/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | TGM2 1522/4885FUT5 87/4885KRAS 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.